World's Best Scientists 2026 revealed!
Sonja Zweegman

Sonja Zweegman

D-Index & Metrics

Medicine

D-Index
91
Citations
35698
World Ranking
11630
National Ranking
448

Sonja Zweegman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sonja Zweegman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 592 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sonja Zweegman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sonja Zweegman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sonja Zweegman is affiliated with Amsterdam UMC in the Netherlands and focuses their research primarily within the field of medicine. Their work extensively covers several subfields including hematology, oncology, molecular biology, immunology, and genetics. The principal topics explored in their research are multiple myeloma research and treatments, protein degradation and inhibitors, CAR-T cell therapy research, peptidase inhibition and analysis, cancer treatment and pharmacology, myeloproliferative neoplasms, and monoclonal and polyclonal antibodies research.

Zweegman has contributed to multiple publications, frequently appearing in journals such as Blood, HemaSphere, Clinical Lymphoma Myeloma & Leukemia, Leukemia, and The Lancet Oncology. Their research collaboration network includes frequent coauthors like Niels W.C.J. van de Donk, Pieter Sonneveld, Philippe Moreau, Thierry Façon, and Annemiek Broijl.

Notable recent papers authored or coauthored by Zweegman include:

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, 2022, Journal of Clinical Oncology
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021, The Lancet Oncology

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

    Anna Van Rhenen;Guus A.M.S. Van Dongen;Angè Le Kelder;Elwin J. Rombouts

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

    M A Dimopoulos;P Moreau;E Terpos;M V Mateos

  • High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

    Anna van Rhenen;Nicole Feller;Angèle Kelder;August H. Westra

  • Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

  • Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Annemiek Broyl;Dirk Hose;Henk Lokhorst;Yvonne de Knegt

  • CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

    Inger S. Nijhof;Inger S. Nijhof;Tineke Casneuf;Jeroen van Velzen;Berris van Kessel

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

    Evangelos Terpos;Martina Kleber;Monika Engelhardt;Sonja Zweegman

  • A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

    Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga

  • Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

    Pierre Wijermans;Martijn Schaafsma;Fabian Termorshuizen;Rianne Ammerlaan

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michele Cavo;Meral Beksac;Lucia Pantani

  • Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

    Claire N. Harrison;Nicolaas Schaap;Alessandro M. Vannucchi;Jean Jacques Kiladjian

  • Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

    Antonio Palumbo;Sara Bringhen;Shaji K Kumar;Giulia Lupparelli

Frequent Co-Authors

Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Michele Cavo
Michele Cavo University of Bologna
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Roman Hájek
Roman Hájek University of Ostrava
Mario Boccadoro
Mario Boccadoro University of Turin
Tuna Mutis
Tuna Mutis Vrije Universiteit Amsterdam
Anders Waage
Anders Waage Norwegian University of Science and Technology
Heinz Ludwig
Heinz Ludwig University of Vienna
Antonio Palumbo
Antonio Palumbo University of Turin
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require attending traditional, on-campus programs. Many students today seek flexible options that fit their lifestyle and financial needs. Online degrees now offer diverse pathways into healthcare, opening doors to specialized fields beyond the typical MD route.

For those interested in healthcare leadership, affordable mha online programs provide an excellent foundation. These degrees prepare graduates for management roles in hospitals, clinics, and public health organizations.

If advanced nursing is your passion, consider dnp online programs cheap. Earning a Doctor of Nursing Practice online can help you take on leadership, clinical, or policy-making positions while balancing current work and family obligations.

Aspiring pharmacists can benefit from accredited programs like pharmacy school online accredited. These options ensure you receive a recognized education essential for licensure and future employment.

Lastly, technology-focused students should explore online mhi degrees. Managing health information is a fast-growing field bridging IT and healthcare, ideal for those interested in both industries.

Best Scientists Citing Sonja Zweegman

Trending Scientists

Recently Published Articles